Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with all data for entry = 50013847
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135413((5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2,3,4...)
Affinity DataIC50: 7nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135417(((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 7nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V2 receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135420(((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 8nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V2 receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135414(Biphenyl-2-carboxylic acid {4-[2-(2-hydroxy-ethyl)...)
Affinity DataIC50: 8nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135419(2-(5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2,3...)
Affinity DataIC50: 12nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135418(3-((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 15nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135415(3-((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 16nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V2 receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135423(Biphenyl-2-carboxylic acid {4-[2-(2-tetrazol-1-yl-...)
Affinity DataIC50: 20nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V2 receptor at 0.2 uMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135420(((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 30nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135418(3-((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 30nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135417(((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 36nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135413((5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2,3,4...)
Affinity DataIC50: 40nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135415(3-((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 40nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135416(Biphenyl-2-carboxylic acid {4-[2-(2-fluoro-ethyl)-...)
Affinity DataIC50: 85nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135414(Biphenyl-2-carboxylic acid {4-[2-(2-hydroxy-ethyl)...)
Affinity DataIC50: 97nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135422(Biphenyl-2-carboxylic acid {4-[2-(2,2-difluoro-eth...)
Affinity DataIC50: 100nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135414(Biphenyl-2-carboxylic acid {4-[2-(2-hydroxy-ethyl)...)
Affinity DataIC50: 100nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135418(3-((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 140nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135414(Biphenyl-2-carboxylic acid {4-[2-(2-hydroxy-ethyl)...)
Affinity DataIC50: 150nMAssay Description:Inhibition of vasopressin induced calcium immobilization in human V1a receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135422(Biphenyl-2-carboxylic acid {4-[2-(2,2-difluoro-eth...)
Affinity DataIC50: 160nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135416(Biphenyl-2-carboxylic acid {4-[2-(2-fluoro-ethyl)-...)
Affinity DataIC50: 180nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135415(3-((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 314nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135421(Biphenyl-2-carboxylic acid [4-(2-dimethylaminometh...)
Affinity DataIC50: 430nMAssay Description:Inhibition of vasopressin induced cAMP accumulation in human V2 receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135417(((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 440nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135413((5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2,3,4...)
Affinity DataIC50: 729nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135413((5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2,3,4...)
Affinity DataIC50: 740nMAssay Description:Inhibition of vasopressin induced calcium immobilization in human V1a receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135420(((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 1.14E+3nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135419(2-(5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2,3...)
Affinity DataIC50: 1.15E+3nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135421(Biphenyl-2-carboxylic acid [4-(2-dimethylaminometh...)
Affinity DataIC50: 1.20E+3nMAssay Description:Ability to displace [3H]arginine vasopressin in cloned human V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135420(((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 1.76E+3nMAssay Description:Inhibition of vasopressin induced calcium immobilization in human V1a receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135418(3-((S)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 2.01E+3nMAssay Description:Inhibition of vasopressin induced calcium immobilization in human V1a receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135417(((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}-2...)
Affinity DataIC50: 2.13E+3nMAssay Description:Inhibition of vasopressin induced calcium immobilization in human V1a receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50135415(3-((R)-5-{4-[(Biphenyl-2-carbonyl)-amino]-benzoyl}...)
Affinity DataIC50: 4.63E+3nMAssay Description:Inhibition of vasopressin induced calcium immobilization in human V1a receptor expressing cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed